Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Salesforce Inc (CRM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Salesforce Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.88 (market cap $4.49B), while Salesforce Inc trades at $166.46 (market cap $138.84B). The key difference: Salesforce Inc is far larger — about 30.9× ACADIA Pharmaceuticals Inc.'s market cap, and Salesforce Inc pays a 1.04% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CRM | |
|---|---|---|
Market Cap | $4.49B | $138.84B |
Sector | Health | Technology |
52-Week High | $28.06 | $273.65 |
52-Week Low | $20.06 | $150.12 |
Enterprise Value | $3.69B | $168.88B |
Dividend Yield | — | 1.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Salesforce (CRM) trades at $166.59, up 0.57% today, with strong fundamentals including 77.64% gross margins and consistent earnings beats. The stock faces technical headwinds with mixed signals from moving averages and oscillators, while analyst consensus remains strongly bullish with a $235.20 price target. Recent news highlights AI-driven growth potential amid sector volatility.
Outlook: CRM's robust profitability and AI monetization (Agentforce ARR up 200% YoY per Seeking Alpha Apr 3) support upside, but near-term risks include software sector sell-offs and RSI overbought conditions. Valuation at 19.64 P/E offers room for growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Salesforce Inc
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Read more on CRM →
